Krystal Biotech, Inc. (NASDAQ:KRYS) is Soleus Capital Management L.P.'s 5th Largest Position

Soleus Capital Management L.P. raised its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 65.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 358,379 shares of the company's stock after acquiring an additional 141,400 shares during the quarter. Krystal Biotech comprises 3.5% of Soleus Capital Management L.P.'s investment portfolio, making the stock its 5th biggest holding. Soleus Capital Management L.P. owned about 1.25% of Krystal Biotech worth $56,144,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. FMR LLC boosted its position in Krystal Biotech by 0.5% during the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after acquiring an additional 21,133 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after purchasing an additional 28,707 shares during the period. Avoro Capital Advisors LLC raised its holdings in shares of Krystal Biotech by 0.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after purchasing an additional 6,600 shares during the period. Hood River Capital Management LLC raised its holdings in shares of Krystal Biotech by 2.1% during the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after purchasing an additional 10,622 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Krystal Biotech by 16.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after purchasing an additional 71,200 shares during the period. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Trading Down 0.2%

Shares of KRYS traded down $0.24 on Friday, reaching $125.05. The company's stock had a trading volume of 298,645 shares, compared to its average volume of 307,417. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $219.34. The stock has a market capitalization of $3.61 billion, a PE ratio of 41.82 and a beta of 0.79. The firm has a fifty day moving average of $161.34 and a 200-day moving average of $167.03.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KRYS has been the topic of several research reports. HC Wainwright reiterated a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, May 6th. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Guggenheim dropped their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Citigroup dropped their price objective on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a report on Friday, May 16th. Finally, Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech currently has an average rating of "Buy" and an average price target of $211.13.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).